30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Elicio Therapeutics Inc (ELTX)

Track

Stock chart
Ticker: ELTX Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Chudnovsky Yekaterina
1 purchase — total 7,047,530 USD
Buy 22 Dec 2023
Value US$4,620,106.71 | Price 259.84 | Shares 95,544
Buy 25 May 2022
Value US$2,430,470.13 | Price 301.30 | Shares 6,657
Buy 24 May 2022
Value US$39,928.00 | Price 1.24 | Shares 32,200
Buy 20 May 2022
Value US$61,500.00 | Price 1.23 | Shares 50,000
Buy 20 May 2022
Value US$2,403.66 | Price 1.18 | Shares 2,037
Buy 19 May 2022
Value US$8,521.36 | Price 1.16 | Shares 7,346
Buy 20 Dec 2021
Value US$8,975.86 | Price 2.54 | Shares 3,527
Planned sale 20 Dec 2021
Value US$938.00 | Price 2.62 | Shares 358
Buy 17 Dec 2021
Value US$34,958.27 | Price 2.54 | Shares 13,742
Buy 16 Dec 2021
Value US$70,992.91 | Price 2.55 | Shares 27,883
Buy 15 Dec 2021
Value US$186,955.80 | Price 2.41 | Shares 77,604
Buy 15 Dec 2021
Value US$9,480.00 | Price 2.37 | Shares 4,000
Planned sale 14 Dec 2021
Value US$1,090.11 | Price 2.42 | Shares 451
Planned sale 6 Dec 2021
Value US$107,720.56 | Price 3.35 | Shares 32,118
Planned sale 3 Dec 2021
Value US$136,216.25 | Price 3.39 | Shares 40,215
Planned sale 2 Dec 2021
Value US$136,327.68 | Price 3.51 | Shares 38,800
Planned sale 1 Dec 2021
Value US$137,666.91 | Price 3.54 | Shares 38,867
Planned sale 18 Nov 2021
Value US$1,544.62 | Price 4.13 | Shares 374
Planned sale 16 Nov 2021
Value US$163,807.77 | Price 4.26 | Shares 38,495
Planned sale 15 Nov 2021
Value US$465,243.46 | Price 4.17 | Shares 111,505
Planned sale 15 Nov 2021
Value US$1,905.20 | Price 4.40 | Shares 433
Planned sale 18 Oct 2021
Value US$3,215.26 | Price 8.62 | Shares 373
Planned sale 14 Oct 2021
Value US$3,719.50 | Price 8.65 | Shares 430
Planned sale 18 Jun 2021
Value US$4,831.20 | Price 13.20 | Shares 366
Planned sale 14 May 2021
Value US$6,124.80 | Price 13.92 | Shares 440
Planned sale 19 Apr 2021
Value US$5,162.55 | Price 13.55 | Shares 381
Sale 17 Mar 2021
Value US$8,455.46 | Price 19.13 | Shares 442
Sale 13 Mar 2021
Value US$10,204.55 | Price 20.45 | Shares 499
Sale 13 Feb 2021
Value US$8,929.78 | Price 19.54 | Shares 457
Sale 9 Feb 2021
Value US$2,546,832.00 | Price 16.00 | Shares 159,177
Sale 9 Feb 2021
Value US$3,947,520.00 | Price 16.00 | Shares 246,720
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2023-12-26 2023-12-22 B Purchase
2.3
Chudnovsky Yekaterina
Non-Executive Director Large shareholder
95,544 -3.6%
259.84
US$4,620,107 		95,544 -3.6% 259.84 US$4,620,107
2022-05-27 2022-05-25 B Purchase
3.5
Venkatesan Jay

See Remarks

Executive Director
6,657 -6.9%
301.30
US$2,430,470 		6,657 -6.9% 301.30 US$2,430,470
2022-05-25 2022-05-24 B Purchase
3.5
Venkatesan Jay

See Remarks

Executive Director
28,545 -23.5%
73.32
US$4,991,244 		28,545 -23.5% 73.32 US$4,991,244
2022-05-25 2022-05-20 B Purchase
3.5
Venkatesan Jay

See Remarks

Executive Director
50,000 +3.1%
1.23
US$61,500 		50,000 +3.1% 1.23 US$61,500
2022-05-23 2022-05-20 B Purchase
2.0
Nissenson Allen
Non-Executive Director
2,037 +27.7%
1.18
US$2,404 		2,037 +27.7% 1.18 US$2,404
2022-05-23 2022-05-19 B Purchase
2.0
Nissenson Allen
Non-Executive Director
7,346 +inf%
1.16
US$8,521 		7,346 +inf% 1.16 US$8,521
2021-12-22 2021-12-20 B Purchase
3.5
Venkatesan Jay

See Remarks

Executive Director
3,527 +0.3%
2.54
US$8,976 		3,527 +0.3% 2.54 US$8,976
2021-12-21 2021-12-20 PlS Planned sale
3.3
Neylan John F.

See Remarks

Officer
358 -1.0%
2.62
US$938 		358 -1.0% 2.62 US$938
2021-12-20 2021-12-17 B Purchase
3.5
Venkatesan Jay

See Remarks

Executive Director
13,742 +1.0%
2.54
US$34,958 		13,742 +1.0% 2.54 US$34,958
2021-12-20 2021-12-16 B Purchase
3.5
Venkatesan Jay

See Remarks

Executive Director
27,883 +2.1%
2.55
US$70,993 		27,883 +2.1% 2.55 US$70,993
2021-12-17 2021-12-15 B Purchase
3.5
Venkatesan Jay

See Remarks

Executive Director
77,604 +6.3%
2.41
US$186,956 		77,604 +6.3% 2.41 US$186,956
2021-12-16 2021-12-15 B Purchase
0.7
CURHAN GREGORY S

See Remarks

Officer
4,000 +inf%
2.37
US$9,480 		4,000 +inf% 2.37 US$9,480
2021-12-15 2021-12-14 PlS Planned sale
3.4
Rhodes Jennifer J

See Remarks

Officer
451 -1.5%
2.42
US$1,090 		451 -1.5% 2.42 US$1,090
2021-12-07 2021-12-06 PlS Planned sale
Goldberg Itzhak

See Remarks

Executive Director
32,118 -1.8%
3.35
US$107,721 		32,118 -1.8% 3.35 US$107,721
2021-12-03 2021-12-03 PlS Planned sale
Goldberg Itzhak

See Remarks

Executive Director
40,215 -2.2%
3.39
US$136,216 		40,215 -2.2% 3.39 US$136,216
2021-12-03 2021-12-02 PlS Planned sale
Goldberg Itzhak

See Remarks

Executive Director
38,800 -2.1%
3.51
US$136,328 		38,800 -2.1% 3.51 US$136,328
2021-12-03 2021-12-01 PlS Planned sale
Goldberg Itzhak

See Remarks

Executive Director
38,867 -2.1%
3.54
US$137,667 		38,867 -2.1% 3.54 US$137,667
2021-11-22 2021-11-18 PlS Planned sale
3.3
Neylan John F.

See Remarks

Officer
374 -1.0%
4.13
US$1,545 		374 -1.0% 4.13 US$1,545
2021-11-17 2021-11-16 PlS Planned sale
Goldberg Itzhak

See Remarks

Officer
38,495 -2.0%
4.26
US$163,808 		38,495 -2.0% 4.26 US$163,808
2021-11-17 2021-11-15 PlS Planned sale
Goldberg Itzhak

See Remarks

Officer
111,505 -5.5%
4.17
US$465,243 		111,505 -5.5% 4.17 US$465,243
2021-11-16 2021-11-15 PlS Planned sale
3.4
Rhodes Jennifer J

See Remarks

Officer
433 -1.4%
4.40
US$1,905 		433 -1.4% 4.40 US$1,905
2021-10-20 2021-10-18 PlS Planned sale
3.3
Neylan John F.

See Remarks

Officer
373 -1.0%
8.62
US$3,215 		373 -1.0% 8.62 US$3,215
2021-10-15 2021-10-14 PlS Planned sale
3.4
Rhodes Jennifer J

See Remarks

Officer
430 -1.4%
8.65
US$3,720 		430 -1.4% 8.65 US$3,720
2021-06-21 2021-06-18 PlS Planned sale
3.3
Neylan John F.

See Remarks

Officer
366 -1.0%
13.20
US$4,831 		366 -1.0% 13.20 US$4,831
2021-05-18 2021-05-14 PlS Planned sale
3.4
Rhodes Jennifer J

See Remarks

Officer
440 -1.3%
13.92
US$6,125 		440 -1.3% 13.92 US$6,125
2021-04-20 2021-04-19 PlS Planned sale
3.3
Neylan John F.

See Remarks

Officer
381 -1.0%
13.55
US$5,163 		381 -1.0% 13.55 US$5,163
2021-03-19 2021-03-17 S Sale
3.3
Neylan John F.

See Remarks

Officer
442 -1.1%
19.13
US$8,455 		442 -1.1% 19.13 US$8,455
2021-03-16 2021-03-13 S Sale
3.4
Rhodes Jennifer J

See Remarks

Officer
499 -1.4%
20.45
US$10,205 		499 -1.4% 20.45 US$10,205
2021-02-17 2021-02-13 S Sale
3.4
Rhodes Jennifer J

See Remarks

Officer
457 -1.3%
19.54
US$8,930 		457 -1.3% 19.54 US$8,930
2021-02-11 2021-02-09 S Sale
3.5
Venkatesan Jay

See Remarks

Executive Director
159,177 -11.6%
16.00
US$2,546,832 		159,177 -11.6% 16.00 US$2,546,832
2021-02-11 2021-02-09 S Sale
3.3
GANZI VICTOR F
Non-Executive Director
246,720 -30.0%
16.00
US$3,947,520 		246,720 -30.0% 16.00 US$3,947,520
Explore more

More insider trading research around Elicio Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America